Expression of c-Jun, p73, Casp9, and N-ras in thymic epithelial tumors: relationship with the current WHO classification systems

Diagnostic Pathology

Jian Wang³  Chen Zhang²  Wei Zhang¹  Xia Liu¹  Na Miao¹  Wenli Cui⁴  Qiaoxin Li⁴  Yuqing Ma¹ 

[1] Department of Pathology, First Affiliated Hospital, Xinjiang Medical University, Urumqi, 830054, China;Fifth Affiliated Hospital, Xinjiang Medical University, Urumqi, China;Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China;Cancer Research Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China

关键词: N-ras;    Casp-9;    p73;    c-Jun;    World Health Organization (WHO);    Histologic classification;    Thymic tumour;   

Others  :  807970
DOI  :  10.1186/1746-1596-7-120

 received in 2012-06-16, accepted in 2012-08-10,  发布年份 2012

【 摘 要 】

Background

To evaluate the expression and differential significance of c-Jun, p73, Casp-9 and N-ras in thymic epithelial tumors (TETs) with the aim to provide useful information for tumor biology and prospective therapy.

Methods

In this study, we analyzed the expression of four chromosome 1-related genes, namely c-Jun, p73, Casp-9 and N-ras, in 60 cases of thymic epithelial tumors. The tumors included 52 thymomas and 8 thymic carcinomas which were categorized according to the current WHO classification systems.

Results

Compared with the normal thymus tissue, all thymic epithelial tumors demonstrated higher expression of c-Jun and p73. The expression of c-Jun and p73 in type B2, B3 thymoma and thymic carcinomas was similar, and significantly higher than that in all other subtypes of thymomas. Unlike type A thymoma, the expression of Casp-9 was relatively lower in type B thymoma and thymic carcinomas. With respect to the clinical staging systems, c-Jun was more expressed in progressive tumors harboring higher stages. In contrast to c-Jun, p73 and Casp-9, there was no significant aberration with N-ras expression irrespective of either tissue or tumor types.

Conclusions

The overexpression of c-Jun, p73 and Casp-9 in thymic epithelial tumors is closely related with the pathogenesis and biological behavior of the neoplasms. These candidate biomarkers provided useful information for prospective personalized therapy in the clinical management.

Additional non-English language abstract language: Chinese

背景:评估c-Jun, p73, Casp-9 和 N-ras在胸腺上皮性肿瘤诊断和鉴别诊断中的运用.

方法:根据世界卫生组织最新的诊断标准60例胸腺上皮性肿瘤分类,运用Envision法检测c-Jun,p73,Casp-9 和N-ras在不同亚型肿瘤中的表达情况,并结合临床病理学特征进行分析.

结果:c-Jun和p73在肿瘤中的表达明显高于正常胸腺组织;c-Jun和p73在B3,B2型胸腺瘤和胸腺癌的表达类似,且表达明显高于其他类型的胸腺肿瘤;Caspase-9在B型胸腺瘤和胸腺癌中的表达相对低于A型胸腺瘤;c-Jun的表达更常见于高级别的胸腺肿瘤.

结论:c-Jun,p73和Casp-9在胸腺肿瘤中的表达很好地反映了肿瘤的生物学特点,为胸腺肿瘤的诊断和鉴别诊断提供了较好的理论基础.

Virtual Slides

http://www.diagnosticpathology.diagnomx.eu/vs/1521774814749726 webcite

【 授权许可】

   
2012 Ma et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Venuta F, Rendina EA, Anile M, de Giacomo T, Vitolo D, Coloni GF: Thymoma and thymic carcinoma. Gen Thorac Cardiovasc Surg 2012, 60:1-12.
• [2]Suster S, Moran CA: Thymoma classification: current status and future trends. Am J Clin Pathol 2006, 125:542-554.
• [3]Chen G, Marx A, Chen WH, Yong J, Puppe B, Stroebel P, Mueller-Hermelink HK: New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer 2002, 95:420-429.
• [4]Masaoka A, Monden Y, Nakahara K, Tanioka T: Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981, 48:2485-2492.
• [5]Koga K, Matsuno Y, Noguchi M, Noguchi M, Mukai K, Asamura H, Goya T, Shimosato Y: A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int 1994, 44:359-367.
• [6]Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC: World Health organization Classification of Tumours: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004.
• [7]Rena O, Papalia E, Maggi G, Oliaro A, Ruffini E, Filosso P, Mancuso M, Novero D, Casadio C: World Health Organization histologic classification: an independent prognostic factor in resected thymomas. Lung Cancer 2005, 50:59-66.
• [8]Rea F, Marulli G, Girardi R, Bortolotti L, Favaretto A, Galligioni A, Sartori F: Long-term survival and prognostic factors in thymic epithelial tumours. Eur J Cardiothorac Surg 2004, 26:412-418.
• [9]Park MS, Chung KY, Kim KD, Yang WI, Chung JH, Kim YS, Chang J, Kim JH, Kim SK, Kim SK: Prognosis of thymic epithelial tumors according to the new World Health Organization histologic classification. Ann Thorac Surg 2004, 78:992-7. discussion 997–998
• [10]Zettl A, Strobel P, Wagner K, Katzenberger T, Ott G, Rosenwald A, Peters K, Krein A, Semik M, Muller-Hermelink HK: Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol 2000, 157:257-266.
• [11]Ma YQ, Zhang C, Cui WL, Gulinaer A, Zhang W, Wang J: Correlation of amplification of chromosome 1 with histologic typing of thymic epithelial tumors. Zhonghua Bing Li Xue Za Zhi 2011, 40:820-824.
• [12]Strobel P, Hohenberger P, Marx A: Thymoma and thymic carcinoma: molecular pathology and targeted therapy. J Thorac Oncol 2010, 5:S286-S290.
• [13]Li J, Liang X, Yang X: Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-kappaB pathways. Oncol Rep 2012, 28(2):501-510.
• [14]Sui H, Fan ZZ, Li Q: Signal Transduction Pathways and Transcriptional Mechanisms of ABCB1/Pgp-mediated Multiple Drug Resistance in Human Cancer Cells. J Int Med Res 2012, 40:426-435.
• [15]Ye B, Wang X, Yang Z, Sun Z, Zhang R, Hu Y, Lu Y, Du J: p53 and p73 Expression in Esophageal Carcinoma Correlate with Clinicopathology of Tumors. Hepatogastroenterology 2012, 59:119.
• [16]Xu W, Jiang S, Xu Y, Chen B, Li Y, Zong F, Zhao W, Wu J: A meta-analysis of caspase 9 polymorphisms in promoter and exon sequence on cancer susceptibility. PLoS One 2012, 7:e37443.
• [17]Kamiya H, Kanno T, Fujita Y, Gotoh A, Nakano T, Nishizaki T: Apoptosis-Related Gene Transcription in Human A549 Lung Cancer Cells via A(3) Adenosine Receptor. Cell Physiol Biochem 2012, 29:687-696.
• [18]Moran CA, Suster S: Neuroendocrine carcinomas of the thymus (thymic carcinoid): clinicopathologic study of 80 cases with a proposal for histologic grading and clinical staging. Am J Clin Path 2000, 114:100-110.
• [19]Alexiev BA, Drachenberg CB, Burke AP: Thymomas: a cytological and immunohistochemical study,with emphasis on lymphoid and neuroendocrine markers. Diagnostic Pathology 2007, 2:13. BioMed Central Full Text
• [20]Rieker RJ, PhA S, Mechterscheimer G, Thomas M, Dienemann H, Schirmacher P, Kern MA: COX-2 expression in thymomas and thymic carcinomas:a novel therapeutic target? Diagnostic Pathology 2007., 2(suppl I)
• [21]Zhou R, Zettl A, Strobel P, Wagner K, Muller-Hermelink HK, Zhang S, Marx A, Starostik P: Thymic epithelial tumors can develop along two different pathogenetic pathways. Am J Pathol 2001, 159:1853-1860.
• [22]Weber KB, Shroyer KR, Heinz DE, Nawaz S, Said MS, Haugen BR: The use of a combination of Galectin-3, and Thyroid peroxidase for the Diagnosis and Prognosis of Thyroid Cancer. Am J Clin Pathol 2004, 122:524-531.
• [23]Sasaki H, Ide N, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y: Gene expression analysis of human thymoma correlates with tumor stage. Int J Cancer 2002, 101:342-347.
• [24]Inoue M, Starostik P, Zettl A, Strobel P, Schwarz S, Scaravilli F, Henry K, Willcox N, Muller-Hermelink HK, Marx A: Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas. Cancer Res 2003, 63:3708-3715.
• [25]Penzel R, Hoegel J, Schmitz W, Blaeker H, Morresi-Hauf A, Aulmann S, Hecker E, Mechtersheimer G, Otto HF, Rieker RJ: Clusters of chromosomal imbalances in thymic epithelial tumours are associated with the WHO classification and the staging system according to Masaoka. Int J Cancer 2003, 105:494-498.
• [26]Davies C, Tournier C: Exploring the function of the JNK (c-Jun N-terminal kinase) signalling pathway in physiological and pathological processes to design novel therapeutic strategies. Biochem Soc Trans 2012, 40:85-89.
• [27]Sabapathy K: Role of the JNK pathway in human diseases. Prog Mol Biol Transl Sci 2012, 106:145-169.
• [28]Ma YQ, Miao N, Abulajiang G, Li QX, Liu X, Zhang W, Wang CF, Wang J: Clinicopathologic analysis of 52 cases of thymic epithelial tumor. Zhonghua Bing Li Xue Za Zhi 2010, 39:249-254.
• [29]Kfir S, Ehrlich M, Goldshmid A, Liu X, Kloog Y, Henis YI: Pathway- and expression level-dependent effects of oncogenic N-Ras: p27(Kip1) mislocalization by the Ral-GEF pathway and Erk-mediated interference with Smad signaling. Mol Cell Biol 2005, 25:8239-8250.
• [30]Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B, Stein H, Dorken B, Jenuwein T, Schmitt CA: Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005, 436:660-665.
• [31]Wolfman JC, Palmby T, Der CJ, Wolfman A: Cellular N-Ras promotes cell survival by downregulation of Jun N-terminal protein kinase and p38. Mol Cell Biol 2002, 22:1589-1606.
• [32]Fu WN, Bertoni F, Kelsey SM, McElwaine SM, Cotter FE, Newland AC, Jia L: Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia. Oncogene 2003, 22:451-455.
• [33]Kuwahara D, Tsutsumi K, Kobayashi T, Hyoudou M, Koizuka I: Inhibition of caspase-9 activity in cisplatin-resistant head and neck squamous cell carcinoma. Nihon Jibiinkoka Gakkai Kaiho 2002, 105:152-157.
• [34]Frank O, Brors B, Fabarius A, Li L, Haak M, Merk S, Schwindel U, Zheng C, Muller MC, Gretz N: Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. Leukemia 2006, 20:1400-1407.
• [35]Lee KE, Hong YS, Kim BG, Kim NY, Lee KM, Kwak JY, Roh MS: p73 G4C14 to A4T14 polymorphism is associated with colorectal cancer risk and survival. World J Gastroenterol 2010, 16:4448-4454.
• [36]Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, Chalas E, Moll UM: DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 2002, 196:765-780.
• [37]Willis AC, Pipes T, Zhu J, Chen X: p73 can suppress the proliferation of cells that express mutant p53. Oncogene 2003, 22:5481-5495.